24/7 Market News – (AMEX:CANF) shares are surging this morning up more than 20% on news that it’s drug showed efficacy for ED.

June 24, 2022

Shares are at 1.07 and climbing.

Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia

https://www.businesswire.com/news/home/20220624005117/en/Can-Fite%E2%80%99s-CF602-Reverses-Erectile-Dysfunction-in-Diabetic-Pre-clinical-Model-Study-Published-in-Peer-Reviewed-Journal-Andrologia

PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced its study titled “A3 adenosine receptor allosteric modulator CF602 reverses erectile dysfunction in a diabetic rat model” was published in the peer-reviewed journal Andrologia.

Pages: 1 2 3

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.